<DOC>
	<DOCNO>NCT02558413</DOCNO>
	<brief_summary>This placebo-controlled , double-blind , randomize , single dose escalation Phase 1 clinical trial determine safety tolerability BTA-C585 administer orally healthy subject .</brief_summary>
	<brief_title>Phase 1 Safety Pharmacokinetics Study Single Ascending Doses BTA-C585 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy men woman age 1860 year ; Weight â‰¥ 50 kg Body Mass Index ( BMI ) 19 32 ; Female subject must nonchildbearing potential ; Male subject must agree use double barrier method birth control ; Able provide inform consent Current recent ( within 14 day Day 0 ) bacterial viral infection ; Positive result hepatitis B , hepatitis C , HIV ; Clinically significant abnormality note ECG ; Safety laboratory abnormality ; Regular use medication , prescription nonprescription ; Poor vein access fear venipuncture ; Major surgery , significant recent injury trauma within 30 day ; Received investigational drug vaccine within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Viral Diseases</keyword>
	<keyword>Antiviral</keyword>
	<keyword>Paramyxoviridae Infections</keyword>
	<keyword>RSV</keyword>
	<keyword>Respiratory Syncytial Virus</keyword>
	<keyword>Aviragen Therapeutics , Inc .</keyword>
	<keyword>Aviragen Therapeutics</keyword>
	<keyword>Aviragen</keyword>
</DOC>